![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC
By
ASCO 2022 Conference Coverage
FEATURING
Michael Overman
By
ASCO 2022 Conference Coverage
FEATURING
Michael Overman
11 views
June 9, 2022
Login to view comments.
Click here to Login
GI